YOUNOSSI Z M , KALLIGEROS M , HENRY L . Epidemiology of metabolic dysfunction‑associated steatotic liver disease [J ] . Clin Mol Hepatol , 2024 , 31 ( Suppl ): S32 ‑ S50 .

范建高 , 徐小元 , 南月敏 , 等 . 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J ] . 实用肝脏病杂志 , 2024 , 27 ( 4 ): 494 ⁃ 510 .

FAN J G , XU X Y , NAN Y M , et al . Guidelines for the prevention and treatment of metabolic dysfunction⁃associated (non⁃alcoholic) fatty liver disease (Version 2024) [J ] . J Prac Hepatol , 2024 , 27 ( 4 ): 494 ⁃ 510 .

SOFTIC S , STANHOPE K L , BOUCHER J , et al . Fructose and hepatic insulin resistance [J ] . Crit Rev Clin Lab Sci , 2020 , 57 ( 5 ): 308 ⁃ 322 .

ZHANG D , TONG X , VANDOMMELEN K , et al . Lipogenic transcription factor ChREBP mediates fructose⁃induced me tabolic adaptations to prevent hepatotoxicity [J ] . J Clin Invest , 2017 , 127 ( 7 ): 2855 ⁃ 2867 .

SALTIEL A R . Insulin signaling in health and disease [J ] . J Clin Invest , 2021 , 131 : e142241 .

DEWIDAR B , MASTROTOTARO L , ENGLISCH C , et al . Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases [J ] . EBioMedicine , 2023 , 94 : 104714 .

LI Y , YANG P , YE J , et al . Updated mechanisms of MASLD pathogenesis [J ] . Lipids Health Dis , 2024 , 23 ( 1 ): 117 .

KOLIAKI C , SZENDROEDI J , KAUL K , et al . Adaptation of hepatic mitochondrial function in humans with non⁃alcoholic fatty liver is lost in steatohepatitis [J ] . Cell Metab , 2015 , 21 ( 5 ): 739 ⁃ 746 .

MEEX R C R , BLAAK E E . Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD [J ] . Mol Nutr Food Res , 2021 , 65 ( 1 ): 1900942 .

LIU R , CHEN L , WANG Y , et al . High ratio of ω⁃3/ω⁃6 polyunsaturated fatty acids targets mTORC1 to prevent high⁃fat diet⁃induced metabolic syndrome and mitochondrial dysfunction in mice [J ] . J Nutr Biochem , 2020 , 79 : 108330 .

FUCHS C D , TRAUNER M . Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology [J ] . Nat Rev Gastroenterol Hepatol , 2022 , 19 ( 7 ): 432 ⁃ 450 .

MASSAFRA V , PELLICCIARI R , GIOIELLO A , et al . Progress and challenges of selective Farnesoid X Receptor modulation [J ] . Pharmacol Ther , 2018 , 191 : 162 ⁃ 177 .

PORTINCASA P , KHALIL M , MAHDI L , et al . Metabolic dysfunction⁃associated steatotic liver disease: from pathogenesis to current therapeutic options [J ] . Int J Mol Sci , 2024 , 25 ( 11 ): 5640 .

CIAULA A D , GARRUTI G , BACCETTO R L , et al . Bile Acid Physiology [J ] . Ann Hepatol , 2017 , 16 ( Suppl 1 ): 4 ⁃ 14 .

BLISON J , SCORLETTI E , SWANN J R , et al . Bile acids as emerging players at the intersection of steatotic liver disease and cardiovascular diseases [J ] . Biomolecules , 2024 , 14 ( 7 ): 841 .

SCHNABL B , DAMMAN C J , CARR R M . Metabolic dysfunction⁃associated steatotic liver disease and the gut microbiome: Pathogenic insights and therapeutic innovations [J ] . J Clin Invest , 2025 , 135 ( 7 ): e186423 .

GUO Q , LI Y , DAI X , et al . Polysaccharides: The potential prebiotics for metabolic associated fatty liver disease (MAFLD) [J ] . Nutrients , 2023 , 15 ( 17 ): 3722 .

ZHANG R , YAN Z , ZHONG H , et al . Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment [J ] . Hepatol Commun , 2024 , 8 ( 7 ): e0484 .

LEUNG C , RIVERA L , FURNESS J B , et al . The role of the gut microbiota in NAFLD [J ] . Nat Rev Gastroenterol Hepatol , 2016 , 13 ( 7 ): 412 ⁃ 425 .

BOVI A P D , MARCIANO F , MANDATO C , et al . Oxidative stress in non⁃alcoholic fatty liver disease. An updated mini review [J ] . Front Med , 2021 , 8 : 595371 .

DALLIO M , SANGINETO M , ROMEO M , et al . Immunity as cornerstone of non⁃alcoholic fatty liver disease: The contribution of oxidative stress in the disease progression [J ] . Int J Mol Sci , 2021 , 22 ( 1 ): 436 .

CHACKELEVICIUS C M , GAMBARO S E , TIRIBELLI C , et al . Th17 involvement in nonalcoholic fatty liver disease progression to non⁃alcoholic steatohepatitis [J ] . World J Gastroenterol , 2016 , 22 ( 41 ): 9096 ⁃ 9103 .

ABDELNABI M N , HASSAN G S , SHOUKRY N H . Role of the type 3 cytokines IL⁃17 and IL⁃22 in modulating metabolic dysfunction⁃associated steatotic liver disease [J ] . Front Immunol , 2024 , 15 : 1437046 .

TANG Y , BIAN Z , ZHAO L , et al . Interleukin⁃17 exacerbates hepatic steatosis and inflammation in non⁃alcoholic fatty liver disease [J ] . Clin Exp Immunol , 2011 , 166 : 281 ⁃ 290 .

GILES D A , MORENO⁃FERNANDEZ M E , DIVANOVIC S . IL⁃17 axis driven inflammation in non⁃alcoholic fatty liver disease progression [J ] . Curr Drug Targets , 2015 , 16 : 1315 ⁃ 1323 .

VACHLIOTIS I D , POLYZOS S A . The role of tumor necrosis factor⁃alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease [J ] . Curr Obes Rep , 2023 , 12 : 191 ⁃ 206 .

NEGRIN K A , ROTH FLACH R J , DISTEFANO M T , et al . IL⁃1 signaling in obesity⁃induced hepatic lipogenesis and steatosis [J ] . PLoS One , 2014 , 9 : e107265 .

POLYZOS S A , KOUNTOURAS J , ZAVOS C , et al . Adipocytokines in insulin resistance and non⁃alcoholic fatty liver disease: The two sides of the same coin [J ] . Med Hypotheses , 2010 , 74 : 1089 ⁃ 1090 .

WANG J , ZHAO J , ZHONG Y , et al . Healthy lifestyle and metabolic associated steatotic liver disease: A study of the efficacy of fatty liver regression [J ] . Clin Transl Gastroenterol , 2025 , 16 ( 2 ): e00806 .

WONG W S , CHAN S M , WONG L H , et al . Community⁃based lifestyle modification programme for non⁃alcoholic fatty liver disease: A randomized controlled trial [J ] . J Hepatol , 2013 , 59 ( 3 ): 536 ⁃ 542 .

YOUNOSSI Z M , ZELBER⁃SAGI S , HENRY L , et al . Lifestyle interventions in nonalcoholic fatty liver disease [J ] . Nat Rev Gastroenterol Hepatol , 2023 , 20 ( 11 ): 708 ⁃ 722 .

KRAVAHUK S , BYCHKOV M , KOZYK M , et al . Managing metabolic dysfunction⁃associated steatotic liver disease (MASLD) in the digital era: Overcoming barriers to lifestyle change [J ] . Cureus , 2025 , 17 ( 5 ): e84803 .

KUMAR A . MASLD pharmacotherapy: Current standards, emerging treatments, and practical guidance for Indian physicians [J ] . J of Assoc Physicians India , 2025 , 73 ( 7 ): e45 ⁃e60.

DRYGALSKI K . Pharmacological treatment of MASLD: Contemporary treatment and future perspectives [J ] . Int J Mol Sci , 2025 , 26 ( 13 ): 6518 .

CHEN M , CHEN Y , LIN J , et al . Evidence summary of lifestyle interventions in adults with metabolic dysfunction⁃associated steatotic liver disease [J ] . Front Nutr , 2025 , 11 : 1421386 .

CUSI K , ISAACS S , BARB D , et al . American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co⁃sponsored by the American Association for the Study of Liver Diseases (AASLD) [J ] . Endocr Pract , 2022 , 28 ( 5 ): 528 ⁃ 562 .

肖瑞 , 万沁 . 代谢功能障碍相关脂肪性肝病的治疗进展 [J ] . 临床内科杂志 , 2025 , 42 ( 5 ): 369 ⁃ 372 .

XIAO R , WAN Q . Advances in the treatment of metabolic dysfunction⁃associated fatty liver disease [J ] . J Clin Intern Med , 2025 , 42 ( 5 ): 369 ⁃ 372 .

MCCAFFREY J M , IBDAH J A . Effects of diet and exercise on mitochondrial health in metabolic dysfunction⁃associated steatotic liver disease (MASLD): Role of ceramides [J ] . Nutrients , 2025 , 17 ( 18 ): 2972 .

RAJEWSKI P , CIESCINSKI J , RAJEWSKI P , et al . Dietary interventions and physical activity as crucial factors in the prevention and treatment of metabolic dysfunction⁃associated steatotic liver disease [J ] . Biomedicines , 2025 , 13 ( 1 ): 217 .

JUREK J M , ZABLOCKA⁃SNOWINSKA K , CLAVERO MESTRES H , et al . The impact of dietary interventions on metabolic outcomes in metabolic dysfunction⁃associated steatotic liver disease (MASLD) and comorbid conditions, including obesity and type 2 diabetes [J ] . Nutrients , 2025 , 17 ( 7 ): 1257 .

SHEIKH M Y , YOUNUS M F , SHERGILL A , et al . Diet and lifestyle interventions in metabolic dysfunction⁃associated fatty liver disease: A comprehensive review [J ] . Int J Mol Sci , 2025 , 26 ( 19 ): 9625 .

SANGRO P , DE LA TORRE ALAZE M , SANGRO B , et al . Metabolic dysfunction⁃associated fatty liver disease (MAFLD): An update of the recent advances in pharmacological treatment [J ] . J Physiol Biochem , 2023 , 79 : 869 ⁃ 879 .

PORTINCASA P , KHALIL M , MAHDI L , et al . Metabolic dysfunction⁃associated steatotic liver disease: From pathogenesis to current therapeutic options [J ] . Int J Mol Sci , 2024 , 25 ( 11 ): 5640 .

李威 , 吕梦竹 , 莫大双 . 非酒精性脂肪性肝病治疗药物Resmetirom 的研发及临床进展 [J ] . 中国医院药学杂志 , 2025 , 45 ( 9 ): 1075 ⁃ 1080 .

LI W , LV M Z , MO D S . Development and clinical progress of resmetirom, a therapeutic drug for non⁃alcoholic fatty liver disease [J ] . Chin J Hosp Pharm , 2025 , 45 ( 9 ): 1075 ⁃ 1080 .

LIU Q K . Mechanisms of action and therapeutic applications of GLP⁃1 and dual GIP/GLP⁃1 receptor agonists [J ] . Front Endocrinol (Lausanne) , 2024 , 15 : 1431292 .

BROUWERS B , RAO G , TANG Y , et al . Incretin⁃based investigational therapies for the treatment of MASLD/MASH [J ] . Diabetes Res Clin Pract , 2024 , 211 : 111675 .

NEWSOME P N , BUCHHOLTZ K , CUSI K , et al . A placebo⁃controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis [J ] . N Engl J Med , 2021 , 384 : 1113 ⁃ 1124 .

PORTINCASA P , KHALIL M , GRAZIANI A , et al . Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations? [J ] . Eur J Intern Med , 2023 , 119 : 13 ⁃ 30 .

PETERSEN M C , VATNER D F , SHULMAN G I . Regulation of hepatic glucose metabolism in health and disease [J ] . Nat Rev Endocrinol , 2017 , 13 : 572 ⁃ 587 .

KLIEWER S A , MANGELSDOR D J . A dozen years of discovery: Insights into the Physiology and Pharmacology of FGF21 [J ] . Cell Metab , 2019 , 29 ( 2 ): 246 ⁃ 253 .

CUI A , LI J , JI S , et al . The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman primates [J ] . Diabetes , 2020 , 69 ( 8 ): 1611 ⁃ 1623 .

ABDELMALEK M F , CHARLES E D , SANYAL A J , et al . The FALCON program: Two phase 2b randomized, double⁃blind, placebo⁃controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis [J ] . Contemp Clin Trials , 2021 , 104 : 106335 .

ALMEQDADI M , GORDON F D . Farnesoid X receptor agonists: a promising therapeutic strategy for gastrointestinal diseases [J ] . Gastro Hep Advances , 2024 , 3 ( 3 ): 344 ⁃ 352 .

JIANG L , ZHANG H , XIAO D , et al . Farnesoid X receptor (FXR): Structures and ligands [J ] . Comput Struct Biotechnol J , 2021 , 19 : 2148 ⁃ 2159 .

LEE J I , LEE H W , LEE K S , et al . Effects of statin use on the development and progression of nonalcoholic fatty liver disease: A nationwide nested case⁃control study [J ] . Am J Gastroenterol , 2021 , 116 : 116 ⁃ 124 .

SFIKAS G , PSALLAS M , KOUMARAS C , et al . Prevalence, diagnosis, and treatment with 3 different statins of non⁃alcoholic fatty liver disease/non⁃alcoholic steatohepatitis in military personnel. Do genetics play a role? [J ] . Curr Vasc Pharmacol , 2021 , 19 : 572 ⁃ 581 .

YUN B , PARK H , LEE J , et al . Statin use and liver⁃related prognosis among patients with MASLD [J ] . JHEP Rep , 2025 , 7 ( 4 ): 101313 .

CARLI F , DELLA PEPA G , SABATINI S , et al . Lipid metabolism in MASLD and MASH: From mechanism to the clinic [J ] . JHEP Rep , 2024 , 6 ( 12 ): 101185 .

倪文婧 , 耿楠 , 白雪 , 等 . 《2024年欧洲肝病学会/欧洲糖尿病学会/欧洲肥胖症学会临床实践指南:代谢相关脂肪性肝病的管理》摘译 [J ] . 临床肝胆病杂志 , 2024 , 40 ( 8 ): 1567 ⁃ 1574 .

NI W J , GENG N , BAI X , et al . An excerpt of EASL⁃EASD⁃EASO clinical practice guidelines on the management of metabolic dysfunction⁃associated steatotic liver disease in 2024 [J ] . J Clin Hepatol , 2024 , 40 ( 8 ): 1567 ⁃ 1574 .

GUDUR A , LAIRD H , SHAH N , et al . Endo⁃bariatric therapies as a treatment strategy for MASLD [J ] . Clin Liver Dis , 2024 , 23 ( 1 ): 1 ⁃ 16 .

杨彬 , 张瑞 . 代谢相关脂肪性肝病治疗进展 [J ] . 中国肝脏病杂志 (电子版), 2024 , 16 ( 04 ): 25 ⁃ 30 .

YANG B , ZHANG R . Progress on the treatment of metabolic associated fatty liver disease [J ] . Chin J Liver Dis (Electronic Version) , 2024 , 16 ( 4 ): 25 ⁃ 30 .